CAS: 125602-71-3; (S)-4-(4-((4-Chlorophenyl)(Pyridin-2-yl)Methoxy)Piperidin-1-yl)Butanoic Acid

上下游产品

Bepotastine
Ethyl (S)-4-[4-[(4-Chlorophenyl)(2-Pyridyl)Methoxy]Piperidino]Butanoate
(S)-2-[(4-氯苯基)(4-哌啶氧基)甲基]吡啶 (S)-(-)-4-[(4-Chlorophenyl)(2-Pyridyl)Methoxy]Piperidine 201594-84-5
2-[(4-氯苯基)(4-哌啶基氧基)甲基]吡啶 2-((4-Chlorophenyl)(Piperidin-4-Yloxy)Methyl)Pyridine 122368-54-1
4-[(4-氯苯基)-2-吡啶基甲氧基]-1-哌啶甲酸乙酯 Ethyl 4-((4-Chlorophenyl)(Pyridin-2-yl)Methoxy)Piperidine-1-Carboxylate 207726-35-0
(S)-Bepotastine L-Menthyl Ester 1092777-17-7
(Rs)-4-[4-[(4-Chlorophenyl)(2-Pyridyl)Methoxy]Piperidino]Butyric Acid D-Menthyl Ester 1560797-65-0
(S)-4-[4-[(4-Chlorophenyl)(2-Pyridyl)Methoxy]Piperidino] Butyric Acid D-Menthyl Ester 1560797-69-4 (4-Chlorophenyl)(Pyridin-2-yl)Methyl 2,2,2-Trichloroacetimidate (S)-(4-Chlorophenyl)(Pyridin-2-yl)Methanol 176022-47-2

(S)-4-[4-[(4-Chlorophenyl)(2-Pyridyl)Methoxy]Piperidin-1-Yl]Butyramide置于水,Sodium Hydroxide体系中,用 乙醇 用作溶剂,以96%的收率获得贝托斯汀
参考文献:一种抗过敏药物贝他斯汀的制备方法
标题:一种抗过敏药物贝他斯汀的制备方法
摘要:本发明公开了一种抗过敏药物贝他斯汀的制备方法,属于抗过敏药物的合成技术领域.本发明的技术方案要点为:以化合物(S)‑(4‑氯苯基)(2‑吡啶基)‑甲醇式(式ii)为起始原料与n‑叔丁氧羰基‑4卤哌啶反应得到化合物(S)‑n‑叔丁氧羰基‑4‑[(4‑氯苯基)(2‑吡啶基)甲氧基]哌啶(式iii);在酸性条件下脱除式(III)化合物的保护基得到化合物(S)‑4‑[(4‑氯苯基)(2‑吡啶基)甲氧基]哌啶式(iv);式(iv)化合物与4‑卤丁酰胺再经亲核取代反应得到化合物(S)‑4‑[(4‑氯苯基)(2‑吡啶基)甲氧基]‑哌啶基]‑丁酰胺(式v),最后式(v)化合物的酰胺基团水解得到目标产物抗过敏药物贝他斯汀.本发明的合成路线简单且成本低廉,适合规模化生产光学纯抗过敏药物贝他斯汀.

专利信息

专利号:WO-2023075715-A1
优先权日:2021-10-26
标题 :A pharmaceutical formulation including leukotriene receptor antagonists and/or leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (nsaids)
发明人：OYTUN FARUK; CAN EFE
权利人:VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI
摘要:This invention is related to a pharmaceutical formulation including Leukotriene receptor antagonists and/or Leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines in ocular diseases and in inflammatory and allergic diseases for systemic and topical use. The objective of this invention is to create a novel formulation to be effective as much as steroids while having significantly less side effects for long-term use in treating ocular diseases, inflammatory and allergic diseases. In other words our aim is to achieve the inhibition of pro-inflammatory mediators (prostaglandins, thromboxane, histamine and leukotrienes) as much as steroids do with a safer combination.

专利号:CN-111100851-A
优先权日:2018-10-25
标 题:Alcohol dehydrogenase mutant and application thereof in synthesis of chiral diaryl alcohol compound

专利号:CN-103121966-A
优先权日:2011-11-17
标题:Directional synthesis of (4-chlorophenyl)-(pyridin-2-yl)-methanol

专利号:CN-111100851-B
优先权日:2018-10-25
标题:Alcohol dehydrogenase mutants and their application in the synthesis of chiral biaryl alcohol compounds

专利号:CN-107827812-A
优先权日:2017-11-23
标 题 :A kind of chiral synthesis method of bepotastine benzenesulfonate intermediate

专利号:CN-106938995-B
优先权日:2017-01-17
标题:A kind of asymmetric synthesis method of ophthalmic drug bepotastine besylate